BTIG lowered the firm’s price target on Lucid Diagnostics to $2.50 from $3 and keeps a Buy rating on the shares. The firm updated its model following Lucid’s Q3 results, where the company beat estimates on revenue, volumes, and ASPs, helped by charges to its revenue cycle management.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LUCD:
- Lucid Diagnostics expands executive team
- Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
- Lucid Diagnostics reports EPS (34c), consensus (27c)
- LUCD Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue